Form 4: Sight Sciences COO Granted 23,006 RSUs

Sight Sciences' Chief Operating Officer, Alison Bauerlein, received a grant of 23,006 restricted stock units valued at approximately $150,000.

Summary

• Alison Bauerlein, Chief Operating Officer of Sight Sciences, Inc. (SGHT), was granted 23,006 shares of common stock in the form of Restricted Stock Units (RSUs).
• The transaction occurred on November 11, 2025, with a price of $0 per RSU, as it was a grant.
• The RSUs were granted under the Issuer's 2021 Incentive Award Plan and are valued at approximately $150,000 based on the stock price on the grant date.
• These RSUs will vest in 16 equal quarterly installments, commencing on December 31, 2025, and continuing through September 30, 2029.
• Vesting is contingent upon Ms. Bauerlein's continued service to Sight Sciences through each vesting date.
• Following this transaction, Ms. Bauerlein beneficially owns 620,526 shares of common stock.

Sentiment

Score: 6

Explanation: The RSU grant is a standard executive compensation event, generally viewed as a positive for executive retention and alignment with shareholder interests, without indicating any immediate operational or financial concerns.

Positives

• The RSU grant aligns the Chief Operating Officer's long-term interests with those of shareholders, incentivizing sustained performance.
• Equity compensation is a common tool for executive retention, helping to secure key talent for the company's strategic objectives.

Negatives

• The issuance of new shares upon RSU vesting could lead to minor dilution for existing shareholders over time, though this is standard for equity compensation plans.

Risks

• The value of the RSUs is subject to the future market price of Sight Sciences' common stock, meaning the actual realized value could be higher or lower than the grant date valuation.
• Vesting is conditional on continued service, posing a risk to the executive if employment ceases before vesting dates.

Future Outlook

The vesting schedule extending through September 2029 indicates an expectation of continued long-term service from the Chief Operating Officer, aligning executive incentives with the company's sustained performance over several years.

Industry Context

The grant of Restricted Stock Units to a key executive is a standard practice in the medical technology and broader corporate sectors. It serves as a common mechanism for executive compensation, aiming to attract, retain, and motivate leadership by linking their financial incentives directly to the company's stock performance and long-term success.

Comparison to Industry Standards

• RSU grants are a prevalent form of equity compensation for executives across various industries, including medical technology. Companies such as Inari Medical (NARI), Shockwave Medical (SWAV), and Penumbra (PEN) frequently utilize similar equity incentive plans to attract and retain top talent.
• The structure of quarterly vesting over several years is typical for executive RSU grants, designed to encourage long-term commitment and performance.
• The valuation of the grant at approximately $150,000 is within the expected range for executive compensation components, though a detailed comparison would require context on the executive's total compensation package and the company's market capitalization relative to peers.

Stakeholder Impact

• Shareholders: Potential for minor dilution upon vesting, but also benefit from increased executive alignment and retention.
• Employees: May signal stability in leadership and a commitment to long-term incentives for key personnel.

Next Steps

• The RSUs will begin vesting in 16 equal quarterly installments starting December 31, 2025.
• Continued service of the Chief Operating Officer is required for the RSUs to vest through September 30, 2029.

Key Dates

Keywords

Sight Sciences, SGHT, Restricted Stock Units, RSU, Executive Compensation, Insider Transaction, Equity Grant, Corporate Governance